Patent ID: 8956619
Filing Date: 2015-02-17
Classification: A61K,C07K

Abstract:
1. A method to inhibit or reduce binding of PD-L1 to PD-1, the method comprising: providing a composition consisting essentially of a soluble chimeric polypeptide in a pharmaceutical carrier wherein the composition is formulated for parenteral administration to a subject, wherein the soluble chimeric polypeptide comprises a CD80 sequence fused to a Fc of a IgG1 sequence in the pharmaceutical carrier, wherein the CD80 sequence consists of the amino acids of SEQ ID NO:4; and contacting a tumor cell of the subject with the composition and soluble chimeric polypeptide; and detecting binding of the soluble chimeric polypeptide to PD-L1 positioned on the tumor cell, wherein the soluble chimeric polypeptide inhibits or reduces the binding of PD-L1 to PD-1.